Gilead Sciences' (GILD) "Sector Perform" Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Gilead Sciences (NASDAQ:GILD - Free Report) in a report published on Monday,Benzinga reports. Royal Bank of Canada currently has a $84.00 price target on the biopharmaceutical company's stock.

Other analysts also recently issued reports about the company. Maxim Group downgraded Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Bank of America reissued a "buy" rating and issued a $109.00 price objective on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.39.

Gilead Sciences Trading Down 1.6 %

Shares of GILD traded down $1.61 during trading hours on Monday, hitting $98.04. The stock had a trading volume of 4,500,131 shares, compared to its average volume of 6,840,460. The company's fifty day simple moving average is $92.86 and its 200 day simple moving average is $86.41. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $100.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market cap of $122.18 billion, a P/E ratio of 1,089.33, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the company earned $2.29 EPS. The company's revenue was up 7.0% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences will post 4.34 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.29% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after acquiring an additional 841,776 shares during the period. Wellington Management Group LLP increased its holdings in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. FMR LLC boosted its stake in shares of Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Gilead Sciences by 2.1% during the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after purchasing an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Gilead Sciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company's stock valued at $739,217,000 after purchasing an additional 249,804 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.